Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma.

Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, Ronen SM.

Neuro Oncol. 2012 Mar;14(3):315-25. doi: 10.1093/neuonc/nor209.

2.

Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.

Sami A, Karsy M.

Tumour Biol. 2013 Aug;34(4):1991-2002. doi: 10.1007/s13277-013-0800-5. Review.

PMID:
23625692
3.

Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.

Barrett D, Brown VI, Grupp SA, Teachey DT.

Paediatr Drugs. 2012 Oct 1;14(5):299-316. doi: 10.2165/11594740-000000000-00000. Review.

4.

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.

Albert S, Serova M, Dreyer C, Sablin MP, Faivre S, Raymond E.

Expert Opin Investig Drugs. 2010 Aug;19(8):919-30. doi: 10.1517/13543784.2010.499121. Review.

PMID:
20569080
5.

PI3K/Akt/mTOR pathway inhibitors in the therapy of pancreatic neuroendocrine tumors.

Wolin EM.

Cancer Lett. 2013 Jul 10;335(1):1-8. doi: 10.1016/j.canlet.2013.02.016. Review.

PMID:
23419523
6.

PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.

Wu P, Hu YZ.

Curr Med Chem. 2010;17(35):4326-41. Review.

PMID:
20939811
7.

Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.

Dienstmann R, Rodon J, Serra V, Tabernero J.

Mol Cancer Ther. 2014 May;13(5):1021-31. doi: 10.1158/1535-7163.MCT-13-0639. Review.

8.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.

Polivka J Jr, Janku F.

Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Review.

PMID:
24333502
9.

Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.

Burris HA 3rd.

Cancer Chemother Pharmacol. 2013 Apr;71(4):829-42. doi: 10.1007/s00280-012-2043-3. Review.

PMID:
23377372
10.

New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).

Feldman ME, Shokat KM.

Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64. Review.

PMID:
20549474
11.

The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.

Slomovitz BM, Coleman RL.

Clin Cancer Res. 2012 Nov 1;18(21):5856-64. doi: 10.1158/1078-0432.CCR-12-0662. Review.

12.

Targeting the PI3K-AKT-mTOR signaling network in cancer.

Khan KH, Yap TA, Yan L, Cunningham D.

Chin J Cancer. 2013 May;32(5):253-65. doi: 10.5732/cjc.013.10057. Review.

13.

Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.

Bartalucci N, Guglielmelli P, Vannucchi AM.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S307-9. doi: 10.1016/j.clml.2013.07.011. Review.

PMID:
24290217
14.

Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.

Beck JT, Ismail A, Tolomeo C.

Cancer Treat Rev. 2014 Sep;40(8):980-9. doi: 10.1016/j.ctrv.2014.06.006. Review.

PMID:
25037117
15.

Development of PI3K inhibitors: lessons learned from early clinical trials.

Rodon J, Dienstmann R, Serra V, Tabernero J.

Nat Rev Clin Oncol. 2013 Mar;10(3):143-53. doi: 10.1038/nrclinonc.2013.10. Review.

PMID:
23400000
16.

Will kinase inhibitors make it as glioblastoma drugs?

Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF.

Curr Top Microbiol Immunol. 2012;355:135-69. doi: 10.1007/82_2011_178. Review.

17.

PI3K and cancer: lessons, challenges and opportunities.

Fruman DA, Rommel C.

Nat Rev Drug Discov. 2014 Feb;13(2):140-56. doi: 10.1038/nrd4204. Review.

18.

Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.

Owonikoko TK, Khuri FR.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e395. Review.

19.

The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals.

Tan HK, Moad AI, Tan ML.

Asian Pac J Cancer Prev. 2014;15(16):6463-75. Review.

20.

Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.

Welker ME, Kulik G.

Bioorg Med Chem. 2013 Jul 15;21(14):4063-91. doi: 10.1016/j.bmc.2013.04.083. Review.

Supplemental Content

Support Center